Bispecific CAR T-cell therapy: combining anti-CD19 and CD22 CAR T-cells - 101793

Spotlight
Video

Bispecific CAR T-cell therapy: combining anti-CD19 and CD22 CAR T-cells

VJHemOnc has 1225 videos Subscribe Here

Loading........
Description: With CAR T-cell therapy, similarly to traditional chemotherapy, the use of a single agent will not remain effective in treating a cancer, and thus multi-agent regimens are needed. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Nirali Shah, MD, of the National Cancer Institute, National Institutes of Health, Bethesda, MD, discusses an exciting upcoming clinical trial, which plans to combine anti-CD22 and anti-CD19 CAR T-cell therapies for patients with B-cell malignancies.
Shared By : VJHemOnc
Posted on : 01/05/18
Added : 7 months ago